Imagion Biosystems has updated investors by lodging the latest version of its corporate presentation visuals with the Australian Securities Exchange. Content includes overviews of MagSense® Technology, the medical needs for clinical MagSense imaging, market sizes and growth rates, development milestones, and more.
View the 25 October 2017 Investor Update.
Imagion Initiates Collaboration with Wayne State University to Develop Advanced Molecular Imaging Capabilities to Enable AI Cancer Diagnostics
August 13, 2025
Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilizing its proprietary MagSense® imaging